Literature DB >> 1374810

Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.

M Robert-Guroff1, K Aldrich, R Muldoon, T L Stern, G P Bansal, T J Matthews, P D Markham, R C Gallo, G Franchini.   

Abstract

In contrast to infrequent and low-titer cross-neutralization of human immunodeficiency virus type 1 (HIV-1) isolates by HIV-2- and simian immunodeficiency virus (SIV)-positive sera, extensive cross-neutralization of HIV-2NIH-Z, SIVMAC251, and SIVAGM208K occurs with high titer, suggesting conservation of epitopes and mechanism(s) of neutralization. The V3 regions of HIV-2 and SIV isolates, minimally related to the HIV-1 homolog, share significant sequence homology and are immunogenic in monkeys as well as in humans. Whereas the crown of the V3 loop is cross-reactive among HIV-1 isolates and elicits neutralizing antibodies of broad specificity, the SIV and especially HIV-2 crown peptides were not well recognized by cross-neutralizing antisera. V3 loop peptides of HIV-2 isolates did not elicit neutralizing antibodies in mice, guinea pigs, or a goat and together with SIV V3 peptides did not inhibit serum neutralization of HIV-2 and SIV. Thus, the V3 loops of HIV-2 and SIV do not appear to constitute simple linear neutralizing epitopes. In view of the immunogenicity of V3 peptides, the failure of conserved crown peptides to react with natural sera implies a significant role of loop conformation in antibody recognition. Our studies suggest that in addition to their grouping by envelope genetic relatedness, HIV-2 and SIV are neutralized similarly to each other but differently from HIV-1. The use of linear peptides of HIV-2 and SIV as immunogens may require greater attention to microconformation, and alternate subunit approaches may be needed in exploiting these viruses as vaccine models. Such approaches may also be applicable to the HIV-1 system in which conformational epitopes, in addition to the V3 loop, participate in virus neutralization.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374810      PMCID: PMC241142     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Persistent infection of rhesus macaques with a molecular clone of human immunodeficiency virus type 2: evidence of minimal genetic drift and low pathogenetic effects.

Authors:  G Franchini; P Markham; E Gard; K Fargnoli; S Keubaruwa; L Jagodzinski; M Robert-Guroff; P Lusso; G Ford; F Wong-Staal
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

2.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

Authors:  G J LaRosa; J P Davide; K Weinhold; J A Waterbury; A T Profy; J A Lewis; A J Langlois; G R Dreesman; R N Boswell; P Shadduck
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

3.  Evolutionary origin of human and simian immunodeficiency viruses.

Authors:  T Gojobori; E N Moriyama; Y Ina; K Ikeo; T Miura; H Tsujimoto; M Hayami; S Yokoyama
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

4.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.

Authors:  M Thali; U Olshevsky; C Furman; D Gabuzda; M Posner; J Sodroski
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

5.  Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

Authors:  K Javaherian; A J Langlois; G J LaRosa; A T Profy; D P Bolognesi; W C Herlihy; S D Putney; T J Matthews
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

6.  The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.

Authors:  C Wilson; M S Reitz; K Aldrich; P J Klasse; J Blomberg; R C Gallo; M Robert-Guroff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

7.  Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III.

Authors:  N L Letvin; M D Daniel; P K Sehgal; R C Desrosiers; R D Hunt; L M Waldron; J J MacKey; D K Schmidt; L V Chalifoux; N W King
Journal:  Science       Date:  1985-10-04       Impact factor: 47.728

8.  Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.

Authors:  S Matsushita; M Robert-Guroff; J Rusche; A Koito; T Hattori; H Hoshino; K Javaherian; K Takatsuki; S Putney
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

9.  Productive infection of both CD4+ and CD4- human cell lines with HIV-1, HIV-2 and SIVagm.

Authors:  A Werner; G Winskowsky; K Cichutek; S G Norley; R Kurth
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

10.  Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA.

Authors:  M Seiki; S Hattori; Y Hirayama; M Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

View more
  22 in total

1.  Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.

Authors:  R E Means; T Greenough; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways.

Authors:  B A Watkins; M S Reitz; C A Wilson; K Aldrich; A E Davis; M Robert-Guroff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

3.  Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein.

Authors:  A McKnight; C Shotton; J Cordell; I Jones; G Simmons; P R Clapham
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

4.  Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.

Authors:  E Jurkiewicz; G Hunsmann; J Schäffner; T Nisslein; W Lüke; H Petry
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

Authors:  S L Buge; L Murty; K Arora; V S Kalyanaraman; P D Markham; E S Richardson; K Aldrich; L J Patterson; C J Miller; S M Cheng; M Robert-Guroff
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins.

Authors:  José Maria Marcelino; Helena Barroso; Fátima Gonçalves; Sofia Marques Silva; Carlos Novo; Perpétua Gomes; Ricardo Camacho; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

7.  Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.

Authors:  José Maria Marcelino; Pedro Borrego; Cheila Rocha; Helena Barroso; Alexandre Quintas; Carlos Novo; Nuno Taveira
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  Simian immunodeficiency viruses from central and western Africa: evidence for a new species-specific lentivirus in tantalus monkeys.

Authors:  M C Müller; N K Saksena; E Nerrienet; C Chappey; V M Hervé; J P Durand; P Legal-Campodonico; M C Lang; J P Digoutte; A J Georges
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

10.  Analysis of simian immunodeficiency virus sequence variation in tissues of rhesus macaques with simian AIDS.

Authors:  T Kodama; K Mori; T Kawahara; D J Ringler; R C Desrosiers
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.